Consequences of menopause in women with diabetes mellitus - A clinical problem

Gynecological Endocrinology

Volumn 21, Issue 5, 2005, Pages 280-286

  Jedrzejuk, Diana ^a   Milewicz, Andrzej ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Diabetes mellitus; Menopause

Indexed keywords

DYDROGESTERONE; ESTRADIOL; ESTROGEN; NORETHISTERONE; PROGESTERONE;

ALTERNATIVE MEDICINE; ARTICLE; BREAST CANCER; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLIMACTERIUM; DIABETES MELLITUS; DISORDERS OF CARBOHYDRATE METABOLISM; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; ENDOMETRIUM CANCER; ESTROGEN THERAPY; EVIDENCE BASED MEDICINE; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; LIFE; MENOPAUSAL SYNDROME; MENOPAUSE; METABOLIC SYNDROME X; NEOPLASM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OSTEOPOROSIS; PATHOLOGY; PHYSICIAN; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; SUGGESTION; THROMBOEMBOLISM;

ADIPOSE TISSUE; AGING; BODY COMPOSITION; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERLIPIDEMIAS; INSULIN RESISTANCE; MENOPAUSE; METABOLIC SYNDROME X; POSTMENOPAUSE;

EID: 29944435610     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590500378964     Document Type: Article

References (69)

1. Milewicz A, Tworowska U, Demissie M. Menopausal obesity-myth of fact? Climacteric 2001;4:273-283.
2. Lamberts SW, van den Belt AW, van der Ley AJ. The endocrinology of aging. Science 1997;278:419-424.
3. Milewicz A, Jedrzejuk D, Bohdanowicz-Pawlak A, Medras M. Metabolic and hormonal changes after DHEA treatment. In: Aso T, Yanaihara T, Taketani Y, Suda T, et al., editors. The 9th International Menopause Society world congress on the menopause, Yokohama (Japan). Bologna: Monduzzi; 1999. pp 215-220.
4. Milewicz A, Zatonska K, Demissie M, Jedrzejuk D, Dunajska K, Ilow R, Lwow F. Serum adiponectin concentration and cardiovascular risk factors in climacteric women. Gynecol Endocrinol 2002;20:68-73.
5. Milewicz A, Demissie M. Metabolic and endocrine changes in climacteric women. In: Samsioe G, Skouby S, editors. Midlife health-current concepts and challenges for the future. Amsterdam: Excerpta Medica/Elsevier Science BV; 2002. pp 3-7 (International congress series; 1229).
6. Freedland ES. Role of a critical visceral adipose tissue threshold (CVATT) in metabolic syndrome: implications for controlling dietary carbohydrates: a review. Nutr Metab 2004;12:1-24.
7. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000;21:697-738.
8. Deng HW, Li J, Li JL, Dowd R, Davies KM, Johnson M, Gong G, Deng H, Recker RR. Association of estrogen receptor-α genotypes with body mass index in normal healthy postmenopausal Caucasian women. J Clin Endocrinol Metab 2000;85:2748-2751.
9. Bottini N, MacMurray J, Peters W, Rostamkhani M, Comings DE. Association of the acid phosphatase (ACP1) gene with triglyceride levels in obese women. Mol Genet Metab 2002;77:226-229.
10. Paterson JM, Morton NM, Fievet C, Kenyon CJ, Holmes MC, Staels B, Seckl JR, Mullins JJ. Metabolic syndrome without obesity; hepatic overexpression of 11β-hydroxysteroid dehydrogenase type 1 in transgenic mice. Proc Natl Acad Sci U S A 2004;101:7088-7093.
11. Milewicz A, Bidzinska B, Mikulski E, Demissie M, Tworowska U. Influence of obesity and menopausal status on serum leptin, cholecystokinin, galanin and neuropeptide Y levels. Gynecol Endocrinol 2000;14:196-200.
12. Sclavo M. Cardiovascular risk factors and prevention in women: similarities and differences. Ital Heart J 2001; 2(2 Suppl):125-141.
13. Dobs AS, Nguyen T, Pace C, Roberts CP. Differential effects of oral estrogen versus oral estrogen - androgen replacement therapy on body composition in postmenopausal women. J Clin Endocrinol Metab 2002;87:1509-1516.
14. The IDF consensus worldwide definition of the metabolic syndrome, Berlin, 14th April 2005. Available: http://www.idf.org
15. Khoo CL, Perera M. Diabetes and the menopause. J Br Menopause Soc 2005;11:6-11.
16. Effects of menopause and estrogen replacement therapy or hormone replacement therapy in women with diabetes mellitus: consensus opinion of the North American Menopause Society. Menopause 2000;7:87-95.
17. Kalish GM, Barrett-Connor E, Laughlin GA, Gulanski BI; Postmenopausal Estrogen/Progestin Intervention Trial. Association of endogenous sex hormones and insulin resistance among postmenopausal women: results from the Postmenopausal Estrogen/Progestin Intervention trial. J Clin Endocrinol Metab 2003;88:1646-1652.
18. Conus F, Allison DB, Rabasa-Lhoret R, St-Onge M, St-Pierre DH, Tremblay-Lebeau A, Poehlman ET. Metabolic and behavioral characteristics of metabolically obese but normal-weight women. J Clin Endocrinol Metab 2004;89: 5013-5020.
19. Hrebicek J, Janout V, Malincikova J, Horakova D, Cizek L. Detection of insulin resistance by simple quantitative insulin sensitivity check index QUICKI for epidemiological assessment and prevention. J Clin Endocrinol Metab 2002;87:144-147.
20. Fisman EZ, Tenenbaum A, Pines A. Systematic hypertension in postmenopausal women: a clinical approach. Curr Hypertens Rep 2002;4:464-470.
21. Pines A. Alternations in cardiac hemodynamics associated with menopause and HRT. In: Neves-e-Castro M, Birkauser M, Clarkson TB, Collins P, editors. Menopause and the heart. New York: Parthenon Publishing; 1999. pp 35-39.
22. Kaseta JR, Skafar DF, Ram JL, Jacober SJ, Sowers JR. Cardiovascular disease in diabetic women. J Clin Endocrinol Metab 1999;84:1835-1838.
23. McFarlane SI, Banerji ML, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001;86: 713-718.
24. Mogul HR, Weinstein BI, Mogul DB, Peterson SJ, Zhang S, Frey M, Gambert SR, Southren AL. Syndrome W: a new model of hyperinsulinemia, hypertension and midlife gain in healthy woman with normal glucose tolerance. Heart Dis 2002;4:78-85.
25. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, Kral JG. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999; 84:1513-1517.
26. Deng HW, Li J, Li JL, Dowd R, Davies KM, Johnson M, Gong G, Deng H, Recker RR. Association of estrogen receptor α genotypes with body mass index in normal healthy postmenopausal Caucasian women. J Clin Endocrinol Metab 2000;85:2748-2751.
27. Reaven GM, Brand RJ, Chen YD, Mathur AK, Goldfine I. Insulin resistance and insulin secretion are determinants of oral glucose tolerance in normal individuals. Diabetes 1993; 42:1324-1332.
28. Milewicz A. Obesity phenotypes, body mass composition and metabolic profile. Endocrinol Obes Metab Disord 2005;1:15-20.
29. Zdrojewski T. Ocena wybranych problemów doryczacych rozpowszechnienia i terapii nadciśnienia tȩtniczego w Polsce na podstawie badania NATPOL-PLUS [Selected problems associated with epidemiology and therapy of hypertension in Poland on the basis of NATPOL-PLUS study]. Medycyna Praktyczna 2002;1-15.
30. Executive summary of the third report of the National Cholesterol Education Program (CEP) Export Panel on Detection, Evaluation and Treatment of High Blond Cholesterol In Adults (Adult Treatment Panel III). J Am Med Assoc 2001;285:2486-2497.
31. Ferrannini E, Natali A. Essential hypertension, metabolic disorders and insulin resistance. Am Heart J 1991;121:1274-1282.
32. Nadel I, Cypryk K, Pertynski T, Sobczuk A, Stetkiewicz T. Studies on the incidence and clinical significance of the metabolic syndrome in postmenopausal women in Lodz region. Pol Arch Med Wewn 2001;106:823-828.
33. Milewicz A, Jedrzejuk D, Lwow F, Bialynicka AS, Lopatynski J, Mardarowicz G, Zahorska-Markiewicz B. Prevalence obesity in Poland. Obes Res 2005;6:113-114.
34. Mahler RJ, Adler ML. Type 2 diabetes mellitus: update on diagnosis, pathophysiology, and treatment. J Clin Endocrinol Metab 1999;84:1165-1171.
35. Perera M, Petrie JR, Hillier C, Small M, Sattar N, Connell JM, Lumsden MA. Hormone replacement therapy can augment vascular relaxation in postmenopausal women with type 2 diabetes. Hum Reprod 2002;17:497-502.
36. Kanaya AM, Herrington D, Vittinghoff E, Lin F, Grady D, Bittner V, Cauley JA, Barrett-Connor E. Heart and Estrogen/progestin Replacement Study. Glycemic effects of postmenopausal hormonal therapy: the Heart and Estrogen/progestin Replacement Study. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2003;138:1-9.
37. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al. Writing Group for the Women's Health Initiative Investigators. Risk and benefits of estrogen and progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002;288: 321-323.
38. Ferrara A, Quesenberry CP, Karter AJ, Njoroge CW, Jacobson AS, Selby JV. Northern California Kaiser Permanente Diabetes Registry. Current use of unopposed estrogen and estrogen plus progestin and the risk of acute myocardial infarction among women with diabetes: the Northern California Kaiser Permanente Diabetes Registry 1995-1998. Circulation 2003;107:43-48.
39. Hippisley-Cox J, Pringle M, Crown N, Coupland C. A case - control study on the effect of hormone replacement therapy on ischaemic heart disease. Br J Gen Pract 2003;53: 191-196.
40. Hayward CS, Samaras K, Campbell L, Kelly RP. Effect of combination hormone replacement therapy on ambulatory blood pressure and arterial stiffness in diabetic postmenopausal women. Am J Hypertens 2001;14:699-703.
41. Ferrara A, Karter AJ, Ackerson LM, Liu JY, Selby JV; Northern California Kaiser Permanente Diabetes Registry. Hormone replacement therapy is associated with better glycemic control in women with type 2 diabetes. The Northern California Kaiser Permanente Diabetes Registry. Diabetes Care 2001;24:1144-1150.
42. Crespo CJ, Smit E, Snelling A, Sempos CT, Andersen RE; NHANES III. Hormone replacement therapy and its relationship to lipid and glucose metabolism in diabetic and nondiabetic postmenopausal women: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2002;25:1675-1680.
43. Godsland IF, Gangar K, Walton C, Cust MP, Whitehead MI, Wynn V, Stevenson JC. Insulin resistance, secretion, and elimination in the post menopausal women receiving oral or transdermal hormone replacement therapy. Metabolism 1993;42:846-853.
44. Luotola H, Pyorala T, Loikkanen M. Effects of natural estrogen/progestagen substitution therapy on carbohydrate and lipid metabolism in postmenopausal women. Maturitas 1986;8:245-253.
45. Crook D, Godsland IF, Hull J, Stevenson JC. Hormone replacement therapy with dydrogesterone and 17-β estradiol: effects on serum lipoproteins and glucose tolerance during 24 months follow up. Br J Obstet Gynaecol 1997;104: 298-304.
46. Zhang Y, Howard BV, Cowan LD, Welty TK, Schaefer CF, Wild RA, Yeh J, Lee ET. Associations of postmenopausal hormone therapy with markers of homeostasis and inflammation and lipid profiles in diabetic and nondiabetic Indian women: the strong heart study. J Womens Health (Larchmt) 2004;13:155-163.
47. Skouby SO, Al-Azzawi F, Barlow D, Calaf-Alsina Erdogan Ertungealp J, Gompel A, Graziottin A, Hudita D, Pines A, Rozenberg S, Samsioe G, et al. Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. Maturitas 2005;51:8-14.
48. Pines A, Bornstein NM, Shapira I. Menopause and ischemic stroke: basic, clinical and epidemiological considerations. The role of hormone replacement. Hum Reprod Update 2002; 8:161-168.
49. Al-Delaimy WK, Willett WC, Manson JE, Speizer FE, Hu FB. Smoking and mortality among women with type 2 diabetes: the Nurses' Health Study cohort. Diabetes Care 2001;24:2043-2048.
50. Rodriguez C, Calle EE, Patel AV, Tatham LM, Jacobs EJ, Thun MJ. Effect of body mass on the association between estrogen replacement therapy and mortality among elderly US women. Am J Epidemiol 2002;153:145-152.
51. Nicodemus KK, Folsm AR. Iowa Women's Health Study: type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 2001;24:1192-1197.
52. Akin O, Gol K, Akturk M, Erkaya S. Evaluation of bone turnover in postmenopausal women with type 2 diabetes mellitus using biochemical markers and bone density measurements. Gynecol Endocrinol 2003;17:19-29.
53. Isaia GC, Ardissone P, Di Stefano M, Ferrari D, Martina V, Porta M, Tagliabue M, Molinatti GM. Bone metabolism in type 2 diabetes mellitus. Acta Diabetol 1999;36:35-38.
54. Stevenson JC. Justification for the use of HRT in the long-term prevention of osteoporosis. Maturitas 2005;51: 113-126.
55. Guastamacchia E, Resta F, Mangia A, Schittulli F, Ciampolillo A, Triggiani V, Licchelli B, Paradiso A, Sabba C, Tafaro E. Breast cancer: biological characteristics in postmenopausal type 2 diabetic women. Identification of therapeutic targets. Curr Drug Targets Immune Endocr Metabol Disord 2003;3:205-209.
56. Zendehdel K, Nyren O, Ostenson CG, Adami HO, Ekbom A, Ye W. Cancer incidence in patients with type 1 diabetes mellitus: a population-based cohort study in Sweden. J Natl Cancer Inst 2003;95:1797-1800.
57. Folsom AR, Anderson KE, Sweeney C, Jacobs DR Jr. Diabetes as a risk factor for death following endometrial cancer. Gynecol Oncol 2004;94:740-745.
58. Svacina S, Matoulek M, Svobodova S, Visokai V, Lipska L, Topolcan O, Zvarova J, Plavcova M. Gastrointestinal tract cancer and diabetes mellitus. Vnitr Lek 2004;50:386-391.
59. Hu FB, Manson JE, Liu S, Hunter D, Colditz GA, Michels KB, Speizer FE, Giovannucci E. Prospective study of adult onset diabetes mellitus (type 2) and risk of colorectal cancer in women. J Natl Cancer Inst 1999;91: 542-547.
60. Dal Maso L, Augustin LS, Karalis A, Talamini R, Franceschi S, Trichopoulos D, Mantzoros CS, La Vecchia C. Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 2004,89:1160-1163.
61. Mantzoros C, Petridou E, Dessypris N, Chavelas C, Dalamaga M, Alexe DM, Papadiamantis Y, Markopoulos C, Spanos E, Chrousos G, et al. Adiponectin and breast cancer risk. J Clin Endocrinol Metab 2004;89:1102-1107.
62. Prisant LM. Preventing type 2 diabetes mellitus. J Clin Pharmacol 2004;44:406-413.
63. Abraham WT. Preventing cardiovascular events in patients with diabetes mellitus. Am J Med 2004;8(Suppl 5A):39S-46S.
64. Milewicz A, Szymanski W, Ruzyllo W, Zgliczynski S, Reinfus M, Zielinski J, Debski R, Demissie M, Tworowska U. Polish consensus: procedure in case of estrogen deficiency in women after breast cancer therapy. Gynecol Endocrinol 2002; 16:385-389.
65. Milewicz A, Jedrzejuk D, Lwow F. Prevention and alternative treatment to HRT in women after breast cancer surgery. Terapia 2002;6:19-23.
66. Shanafelt TD, Barton DL, Adjei AA, Loprinzi CL. Pathophysiology and treatment of hot flashes. Mayo Clin Proc 2002;77:1207-1218.
67. Keegan TH, Schwartz AV, Bauer DC, Sellmeyer DE, Kelsey JL. The fracture intervention trial. Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial. Diabetes Care 2004;27:1547-1553.
68. Maugeri D, Panebianco P, Rosso D, Calanna A, Speciale S, Santangelo A, Rizza I, Motta M, Lentini A, Malaguarnera M. Alendronate reduces the daily consumption of insulin (DCI) in patients with senile type 1 diabetes and osteoporosis. Arch Gerontol Geriatr 2002;34:117-122.
69. Panagiotakos DB, Polychronopulos E. The role of Mediterranean diet in the epidemiology of metabolic syndrome; converting epidemiology to clinical practice. Lipids Health Dis 2005;4:7.